Drug Type Small molecule drug |
Synonyms Acorafloxacin (USAN), Acorafloxacin Hydrochloride, Avarofloxacin + [4] |
Mechanism Bacterial DNA gyrase inhibitors, Top II inhibitors(Topoisomerase II inhibitors), Topoisomerase IV inhibitors + [1] |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H23F2N3O4 |
InChIKeyVMKVDAAFMQKZJS-LFIBNONCSA-N |
CAS Registry878592-87-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10435 | Acorafloxacin | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Complicated skin and skin structure infection | Phase 2 | US | 01 Jun 2010 | |
Community-acquired bacterial pneumonia | Phase 1 | HU | 01 Oct 2010 | |
Community-acquired bacterial pneumonia | Phase 1 | DE | 01 Oct 2010 | |
Community-acquired bacterial pneumonia | Phase 1 | US | 01 Oct 2010 | |
Community-acquired bacterial pneumonia | Preclinical | CA | 01 Oct 2010 | |
Community-acquired bacterial pneumonia | Preclinical | PL | 01 Oct 2010 | |
Community-acquired bacterial pneumonia | Preclinical | CO | 01 Oct 2010 | |
Pneumonia | Preclinical | - | - | |
Skin and skin structure infections | Preclinical | - | - | |
Complicated skin and soft tissue infection | Discovery | US | - |